Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FC084 camphorsulfonate tablets plus tislelizumab in advanced malignant solid tumors
CTR20243910Phase 2Active
- Sponsor
- Inovision Pharma
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FC084, tislelizumab in Nonhematologic neoplasms, bronchial carcinoma, sponsored by Inovision Pharma. Started Dec 2024; status: active.
02
Drugs
FC084tislelizumab
03
Conditions
Nonhematologic neoplasmsbronchial carcinoma
Beyond the preview
Go deeper on CTR20243910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243910.